日本国内では2020年9月までにジェネリック医薬品の使用割合を80％にする目標を挙げています。このような中、Generics Bulletinはグローバルな専門アナリスト＆ジャーナリストの広範なネットワークを駆使して、世界中の市場動向を追跡することで、貴重なニュースを提供しています。また、市場プレーヤーのトップエグゼクティブやオピニオンリーダーのインタビューなども定期的に掲載しています。
深い専門性と具体的なデータに基づいたニュースレポートは、世界の大手ジェネリック医薬品メーカーの戦略を明らかにし、その計画、ポートフォリオ、業績を分析＆報告します。
Generics Bulletinでは以下のトピックをカバーしています。
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
After a production setback, Aspen and Johnson & Johnson announce a donation of 300,000 vaccines to South African teachers. Strides partners with Ennaid for an oral COVID drug, while Dr Reddy’s, Lupin, Cipla and Sun Pharma Partner with Eli Lilly for baricitinib in India and Formycon receives approval for early action for its COVID-19 drug.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Celltrion has pushed into another new market with its Remsima SC subcutaneous version of infliximab, launching the innovative biosimilar in Canada.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
As India sees a consistent rise in daily cases and deaths due to COVID-19, the off-patent industry is stepping up to make drugs affordable and available. Zydus Cadila is seeking approval for virafin, while Natco has applied for molnupiravir approval. Vaccine production and availability has also come under focus.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Guidance published by the US FDA in the form of a question-and-answer document addresses questions from ANDA applicants about generic drug development during the COVID-19 pandemic.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Guidance on protecting participants in bioequivalence studies during the COVID-19 pandemic has been published by the FDA.
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Reforms set out by the European Commission to better prepare the EU for future health crises must heed key lessons learned from experiences of the COVID-19 pandemic, such as the benefits of digitalization, Medicines for Europe has urged.
Topic Coronavirus EU Policy & Regulation
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Glenmark has received the go-ahead in India for and launched its low-priced favipiravir product for mild to moderate COVID-19 under an accelerated approval process.
Topic Coronavirus drug-review
Generics Bulletin: ジェネリック＆バイオシミラーニュース
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Topic Coronavirus
Generics Bulletin: ジェネリック＆バイオシミラーニュース
A second wave of COVID-19 infection later this year would put even greater pressure on drugs used in patients hospitalized with serious respiratory problems, a new report warns.
Topic Coronavirus Distribution
Generics Bulletin: ジェネリック＆バイオシミラーニュース
In the first part of an exclusive two-part interview, James Burt – Accord’s executive vice-president for Europe, the Middle East and North Africa – talks to Generics Bulletin about the key actions taken by the generics industry to mitigate the coronavirus pandemic, and the changed landscape that the off-patent arena can expect to see in future.
Topic Coronavirus Manufacturing
Generics Bulletin: ジ...
30 Jul 2021
Generics Bulletin: ジ...
30 Jul 2021
Generics Bulletin: ジ...
30 Jul 2021
Generics Bulletin: ジ...
30 Jul 2021
Generics Bulletin: ジ...
30 Jul 2021
Generics Bulletin: ジ...
29 Jul 2021
Generics Bulletin: ジ...
29 Jul 2021
Generics Bulletin: ジ...
29 Jul 2021
Generics Bulletin: ジ...
28 Jul 2021
Generics Bulletin: ジ...
28 Jul 2021
Generics Bulletin: ジ...
28 Jul 2021
Generics Bulletin: ジ...
27 Jul 2021
Generics Bulletin: ジ...
27 Jul 2021
Generics Bulletin: ジ...
27 Jul 2021
Generics Bulletin: ジ...
27 Jul 2021
UK
Aidan specializes in
+22 year(s) experience
UK
Duncan specializes in
+21 year(s) experience
UK
Andrea specializes in
+17 year(s) experience
無料トライアルお申込み
お問い合わせ先
新型コロナウイルス感染拡大防止のため在宅勤務を実施しています。お問い合わせの際は下記のフォームまたはメールアドレスをご利用下さい。
Eメール：inquiry.jp@informa.com
レポートストア
オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。
お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。
